HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Rose Sheet

Executive Summary

Avon president moves on: After a "highly successful," five-year career with Avon, Elizabeth Smith is leaving the company, effective Oct. 30, in pursuit of a chief executive officer position. Smith came to "the company for women" as executive VP and brand president in January 2005, and seven months later took control of Avon's North American business. She has been president of the firm since September 2007, overseeing its Marketing, Sales, Supply Chain and IT divisions and playing "an instrumental role in repositioning the business for long-term sustainable growth," according to Sept. 17 release. Avon announced in July that with its ongoing efforts the company remains on track to achieve roughly $200 million in annualized savings by 2012-2013 (1"The Rose Sheet" July 27, 2009, In Brief). "Over the past five years, Liz has partnered closely with me as we have executed the company's turnaround plan," says CEO Andrea Jung. "Most recently as president, she has successfully driven the global integration of our key business processes and technology, helping us develop the requisite infrastructure and wiring to capitalize on our global size and scale." Smith's units now report to Jung

You may also be interested in...



Avon restructuring update

Avon will incur a $90 mil. charge in the second quarter of 2009 related to restructuring activities, firm announces July 22. About $77 mil. is attributed to costs to implement realignments of supply-chain manufacturing operations in North America, Western Europe and Central and Eastern Europe, while $13 mil. relates to changes out of Avon's 2005 restructuring program. Effort will result in the elimination of approximately 1,200 positions when the initiatives are fully implemented by 2012-2013. In North America, the restructuring will involve closing Avon's Springdale, Ohio facility by 2012 to shift manufacturing to Morton Grove, Ill., Celaya, Mexico and contract manufacturers. Avon will also streamline operations in Russia, Latin America and Western Europe. Once implemented, the initiatives will reflect nearly half the costs required to put Avon's 2009 restructuring program into place. "We are on track to achieve our stated goal of approximately $200 mil. in total annualized savings by 2012-2013, with costs to implement all initiatives expected to be in the range of $300-$400 mil.," says Charles Cramb, Avon's vice chairman, chief finance and strategy officer. Firm announced new targets in its ongoing restructuring initiative in February (1"The Rose Sheet" Feb. 23, 2009, In Brief)

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel